These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. Ko WC; Lee HC; Chiang SR; Yan JJ; Wu JJ; Lu CL; Chuang YC J Antimicrob Chemother; 2004 Feb; 53(2):393-5. PubMed ID: 14729739 [TBL] [Abstract][Full Text] [Related]
12. Amikacin and colistin for treatment of Acinetobacter baumannii meningitis. Fulnecky EJ; Wright D; Scheld WM; Kanawati L; Shoham S J Infect; 2005 Dec; 51(5):e249-51. PubMed ID: 15913780 [TBL] [Abstract][Full Text] [Related]
13. Combination carbapenem-sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Lee NY; Wang CL; Chuang YC; Yu WL; Lee HC; Chang CM; Wang LR; Ko WC Pharmacotherapy; 2007 Nov; 27(11):1506-11. PubMed ID: 17963460 [TBL] [Abstract][Full Text] [Related]
14. Colistin, meropenem and rifampin in a combination therapy for multi-drug-resistant Acinetobacter baumannii multifocal infection. A case report. Biancofiore G; Tascini C; Bisà M; Gemignani G; Bindi ML; Leonildi A; Giannotti G; Menichetti F Minerva Anestesiol; 2007 Mar; 73(3):181-5. PubMed ID: 17159765 [TBL] [Abstract][Full Text] [Related]
15. Identification of multidrug- and carbapenem-resistant Acinetobacter baumannii in Canada: results from CANWARD 2007. McCracken M; DeCorby M; Fuller J; Loo V; Hoban DJ; Zhanel GG; Mulvey MR J Antimicrob Chemother; 2009 Sep; 64(3):552-5. PubMed ID: 19578083 [TBL] [Abstract][Full Text] [Related]
16. Preventing strategy of multidrug-resistant Acinetobacter baumanii susceptible only to colistin in cardiac surgical intensive care units. Mastoraki A; Douka E; Kriaras I; Stravopodis G; Saroglou G; Geroulanos S Eur J Cardiothorac Surg; 2008 Jun; 33(6):1086-90. PubMed ID: 18339553 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. Gleeson T; Petersen K; Mascola J J Antimicrob Chemother; 2005 Sep; 56(3):602-3. PubMed ID: 16046467 [No Abstract] [Full Text] [Related]
18. Risk factors for nosocomial imipenem-resistant Acinetobacter baumannii infections. Baran G; Erbay A; Bodur H; Ongürü P; Akinci E; Balaban N; Cevik MA Int J Infect Dis; 2008 Jan; 12(1):16-21. PubMed ID: 17513154 [TBL] [Abstract][Full Text] [Related]
19. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. Bassetti M; Repetto E; Righi E; Boni S; Diverio M; Molinari MP; Mussap M; Artioli S; Ansaldi F; Durando P; Orengo G; Bobbio Pallavicini F; Viscoli C J Antimicrob Chemother; 2008 Feb; 61(2):417-20. PubMed ID: 18174197 [TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal fluid penetration and pharmacokinetic/pharmacodynamic parameters of intravenously administered colistin in a case of multidrug-resistant Acinetobacter baumannii meningitis. Jiménez-Mejías ME; Pichardo-Guerrero C; Márquez-Rivas FJ; Martín-Lozano D; Prados T; Pachón J Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):212-4. PubMed ID: 11957024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]